×
About 877,124 results

Re-Opening the Economy and Getting Back to Business: Business Owners’ Liability Risk When Dealing With Customers and Others
https://www.natlawreview.com/article/re-opening-economy-and-getting-back-to-business-business-owners-liability-risk-when

While the “right” time to open the economy is hotly debated, many states have made the decision that it is time to get back to business. That means that businesses will be opening while there is still a continuing risk of COVID-19 exposure. As long as the risk of exposure remains, businesses face potential liability when they allow customers, vendors, and other parties to enter their premises...

Copper Won’t Save You From Coronavirus
https://www.nytimes.com/article/copper-coronavirus-masks.html?algo=identity&fellback=false&imp_id=973064323&action=click&module=Science Technology&pgtype=Homepage

Pandemic fears have created interest in metallic products touting antimicrobial properties. But experts have doubts about the copper craze.

Why copper could help prevent future pandemic, and what it does to coronavirus
https://www.cleveland.com/news/2020/03/why-copper-could-help-prevent-future-pandemic-and-what-it-does-to-coronavirus.html

A recent clinical study that indicates copper is far better than other common materials at preventing the spread of infectious diseases has caught the public’s attention amid the ongoing coronavirus pandemic.

Business Beware: Premise Liability in the Age of the COVID-19 Economic Restart
https://www.jdsupra.com/legalnews/business-beware-premise-liability-in-97643

Covid-19 makes us face the hazy line between ‘elective’ and ‘essential’ medicine
https://www.washingtonpost.com/outlook/coronavirus-elective-essential-medicine/2020/06/18/d1942ea2-af1e-11ea-8758-bfd1d045525a_story.html

An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
https://stories.gilead.com/articles/an-open-letter-from-daniel-oday-june-22

After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently give...

Hospitals won't release number of workers with COVID-19; nurses union urges transparency
https://www.10tv.com/article/news/local/hospitals-wont-release-number-workers-covid-19-nurses-union-urges-transparency-2020-apr/530-39d6033b-9ec9-4ea4-8307-3f90e3194c3a

Amid push toward transparency, several Portland-area hospitals won’t disclose coronavirus patient tallies
https://www.oregonlive.com/coronavirus/2020/03/amid-push-toward-transparency-several-portland-area-hospitals-wont-disclose-coronavirus-patient-tallies.html

There are so many coronavirus myths that even Snopes can’t keep up
https://www.washingtonpost.com/media/2020/04/15/coronavirus-misinformation-snopes/

A silent epidemic
https://news.harvard.edu/gazette/story/2020/04/one-third-of-hospitalized-covid-19-patients-show-signs-of-delirium/
Stephanie Dutchen

Geriatrician Sharon Inouye on the need to combat delirium in COVID-19 patients

This coronavirus mutation has taken over the world. Scientists are trying to understand why.
https://www.washingtonpost.com/science/2020/06/29/coronavirus-mutation-science/?arc404=true

A mutation affecting the virus's spike protein changed amino acid 614 from “D” (aspartic acid) to “G” (glycine). Research suggests that this small change — which affects three identical amino acid chains — might make the spike protein more effective, enhancing the virus’s infectiousness.

Mutation Allows Coronavirus to Infect More Cells, Study Finds. Scientists Urge Caution.
https://www.nytimes.com/2020/06/12/science/coronavirus-mutation-genetics-spike.html

Geneticists said more evidence is needed to determine if a common genetic variation of the virus spreads more easily between people.

‘They Want to Kill Me’: Many Covid Patients Have Terrifying Delirium
https://www.nytimes.com/2020/06/28/health/coronavirus-delirium-hallucinations.html

To a startling degree, many coronavirus patients are reporting similar experiences. Called hospital delirium, the phenomenon has previously been seen mostly in a subset of older patients, some of whom already had dementia, and in recent years, hospitals adopted measures to reduce it.

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

Expert Perspective on ASCO20 Gastrointestinal Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200231/full/

Jul 1st, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 2nd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival with secondary cytoreductive surgery (53.7 months) compared with no surgery (46 months).

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

COVID-19 in Racial and Ethnic Minority Groups
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html
CDC

The effects of COVID-19 on the health of racial and ethnic minority groups is still emerging; however, current data suggest a disproportionate burden of illness and death among racial and ethnic minority groups. A recent CDC MMWR report included race and ethnicity data from 580 patients hospitalized with lab-confirmed COVID-19 found that 45% of individuals for whom race or ethnicity data was av...

An Oral History of Coronavirus: Testimonies about the pandemic
https://www.washingtonpost.com/graphics/2020/national/coronavirus-oral-history/

An Oral History of COVID-19 From Doctors & Frontline Workers